Cencora, Inc. $COR Shares Sold by Kepler Cheuvreux Suisse SA

Kepler Cheuvreux Suisse SA lowered its position in shares of Cencora, Inc. (NYSE:COR) by 11.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,749 shares of the company’s stock after selling 3,175 shares during the quarter. Kepler Cheuvreux Suisse SA’s holdings in Cencora were worth $8,089,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kemnay Advisory Services Inc. purchased a new stake in shares of Cencora during the fourth quarter worth approximately $25,000. Oakworth Capital Inc. acquired a new stake in Cencora during the 4th quarter worth $26,000. Elyxium Wealth LLC acquired a new stake in Cencora during the 4th quarter worth $27,000. Archer Investment Corp grew its holdings in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC purchased a new stake in shares of Cencora during the fourth quarter worth $29,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Cencora stock opened at $296.43 on Friday. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The stock has a market cap of $57.67 billion, a P/E ratio of 22.73, a PEG ratio of 1.65 and a beta of 0.58. The company has a 50-day moving average price of $277.91 and a 200 day moving average price of $320.37. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same period last year, the firm earned $4.42 earnings per share. Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio is currently 18.40%.

Cencora declared that its board has authorized a share repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

COR has been the topic of several research reports. William Blair assumed coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Barclays cut their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Morgan Stanley set a $342.00 target price on shares of Cencora in a research note on Friday, May 8th. Finally, Weiss Ratings cut Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Eleven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $367.75.

Insiders Place Their Bets

In other Cencora news, Director Lauren M. Tyler acquired 550 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.